EMA Takes Action on Metamizole-Induced Risks

The European Medicines Agency (EMA) has announced new recommendations to mitigate the risks associated with agranulocytosis, a serious side effect linked to the painkiller metamizole. The safety committee, known as PRAC, emphasized the need for increased awareness and revised patient guidance to address this potentially life-threatening condition.

Understanding Agranulocytosis

Agranulocytosis is characterized by a significant reduction in granulocytes, a type of white blood cell, which can lead to severe infections. It can occur at any point during metamizole treatment or shortly after discontinuation, even in patients who have previously tolerated the medication. Notably, the occurrence of agranulocytosis is not dose-dependent, and existing risk minimization strategies vary across EU member states.

Review Initiated by Finland

This review was prompted by concerns raised by the Finnish medicines agency, which reported ongoing cases of agranulocytosis despite enhanced safety measures in Finland. Following an evaluation of available data, PRAC determined that the product information for metamizole must be updated to better inform both healthcare professionals and patients about the risks involved.

New Recommendations for Patients and Professionals

PRAC has advised healthcare providers to instruct patients to cease using metamizole and seek immediate medical assistance if they exhibit symptoms of agranulocytosis, which include fever, chills, sore throat, and painful sores in mucosal areas. Patients are urged to remain vigilant for these symptoms both during treatment and shortly after stopping the medication.

Additionally, the committee underscored the importance of testing blood cell levels immediately upon symptom onset, with treatment to be halted until results are obtained. Metamizole is contraindicated for individuals at an increased risk of agranulocytosis, including those with prior experiences of the condition due to metamizole or similar medications.

Ongoing Use of Metamizole

Despite these risks, PRAC concluded that the benefits of metamizole still outweigh the dangers, prompting an update to the product information to enhance awareness and early detection of agranulocytosis. The revised recommendations will be forwarded to the CMDh for further consideration in their upcoming meeting.

Background on Metamizole

Metamizole, also known as dipyrone, has been used in the EU since the 1920s and is prescribed for moderate to severe pain and fever. It is available in various forms and under multiple brand names across numerous EU countries. However, it will soon be withdrawn from the Finnish market due to these safety concerns.

Highlights

• EMA's PRAC recommends measures to address agranulocytosis risk linked to metamizole.
• Agranulocytosis can occur at any time and is not dose-dependent.
• Patients must be vigilant for symptoms and seek immediate medical attention if they arise.
• Metamizole's benefits still outweigh the risks according to PRAC.
• Updated product information will be distributed to enhance awareness among healthcare professionals and patients.